Sacré A, Barthélémy P, Korenbaum C, Burgy M, Wolter P, Dumez H, Lerut E, Loyson T, Joniau S, Oyen R, Debruyne PR, Schöffski P, Beuselinck B. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. AO [Internet]. 2016 Mar. 3 [cited 2024 Jun. 27];55(3):329-40. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/25233